Press Release Feb 13 2026
Filed with NSE · · 3 pages · English
Ref: Akums/Exchange/2025-26/80 February 13, 2026 Sub: Press Release Respected Sir/Madam, Dharamvir Malik Company Secretary & Compliance Officer Encl: as above Registered Office Akums delivers strong Q3 FY26 performance with 14.8% revenue growth and 21% Adj EBITDA growth New Delhi, February 13 2026: Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizat
Akums Drugs and Pharmaceuticals Limited on 6ix
In the deck
Earlier from Akums Drugs and Pharmaceuticals
- Press Release Nov 13 2025
- Akums Receives ANVISA GMP Certification for Sterile Manufacturing Plant, Expands Global Sterile Manufacturing Footprint
- Press Release Aug 08 2025
- Press Release May 26 2025
- Press Release Feb 06 2025
Later from Akums Drugs and Pharmaceuticals
- Akums Strengthens European and UK Presence -- India's Largest CDMO Expands Global Footprint
- Press Release May 14 2026
- Akums Drugs And Pharmaceuticals Limited Press Release Aug 08 2026
Follow Akums Drugs and Pharmaceuticals into a list and get an email when it puts out news.
Follow Akums Drugs and Pharmaceuticals